Johar Dina
Department of Physiology and Pathophysiology, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
J Cell Physiol. 2018 Mar;233(3):2146-2161. doi: 10.1002/jcp.25950. Epub 2017 Jun 15.
Neonatal pulmonary hypertension (PHN) is a lethal progressive disease that occurs in prenatal circulatory transition. Mechanical wall strain caused by cardiac pulsation integrates with hypoxia to generate rapidly progressive myocyte cytoskeleton disassembly and failure to exert force generation. The physiological responses to such an interaction have not been investigated. The persistent phenotype does not respond to traditional vasodilator therapy; hence, there is a need for new treatment strategies to improve the morbidity and mortality outcomes. We reviewed the current research methods, models, and markers of persistent PHN relevant to oxidative and nitrosative stress as well as cell fate commitment, with an emphasis on apoptosis and proliferation. We surveyed potential investigations into the role of senescence in neonatal PHN cell fate decision programming during vasodilator treatment and suggested putative drug targets to improve clinical outcomes. We identified important signaling intermediates of senescence and cell cycle entry regulation in hypertensive pulmonary arterial tissues.
新生儿肺动脉高压(PHN)是一种发生在产前循环转变过程中的致命性进展性疾病。心脏搏动引起的机械壁应变与缺氧共同作用,导致心肌细胞骨架迅速解体,并无法产生力量。尚未对这种相互作用的生理反应进行研究。持续性表型对传统血管扩张剂治疗无反应;因此,需要新的治疗策略来改善发病率和死亡率。我们回顾了与氧化应激和亚硝化应激以及细胞命运决定相关的持续性PHN的当前研究方法、模型和标志物,重点关注细胞凋亡和增殖。我们调查了关于衰老在血管扩张剂治疗期间新生儿PHN细胞命运决定编程中的作用的潜在研究,并提出了可能改善临床结果的药物靶点。我们确定了高血压肺动脉组织中衰老和细胞周期进入调节的重要信号中间体。